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Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by many different cell types, and skeletal muscle is an
important source of IL-6 during exercise. Here, we studied the effects of glucose deprivation in vitro on skele-
tal muscle-derived IL-6 expression and release in C2C12 myocytes, as well as its regulation by p38 mitogen-
activated protein kinase (p38MAPK) and reactive oxygen species (ROS). C2C12 myotubes were cultured in
DMEM medium containing 4.5 g  L−1 glucose (glucose control, GC) or DMEM medium containing no glucose
(glucose deprivation, GD) for 0, 6, 12, 18 and 24 hours, and then incubated with 10 mM NAC (a ROS scavenger)
or 10 μM SB203580 (a p38MAPK inhibitor) under either GC or GD conditions for 24 hours. IL-6 expression
levels were subsequently analyzed using RT–PCR, and IL-6 protein levels in the medium were measured
using ELISA. Glucose deprivation significantly enhanced IL-6 expression at 18 and 24 hours compared to the
glucose control, and caused IL-6 protein levels to increase significantly over the entire 24-hour measurement
period. The ROS scavenger NAC inhibited the glucose deprivation-induced release of IL-6 protein almost
completely, while the p38MAPK inhibitor SB203580 inhibited glucose deprivation-induced IL-6 protein release
to a lesser extent. Our study suggests that glucose deprivation in C2C12 myocytes induces IL-6 expression
and release, and that this IL-6 release is mainly mediated via ROS signaling. Skeletal muscle-derived IL-6 
may thus play an important role in energy metabolism during exercise. [J Exerc Sci Fit • Vol 9 • No 2 •
123–127 • 2011]
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Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine secreted
by many different cell types, and recent studies have
shown that it is linked to obesity and insulin resistance
(Allen & Febbraio 2010). For example, IL-6-deficient
mice developed mature-onset obesity and insulin resis-
tance (Klover et al. 2005; Wallenius et al. 2002). Previous
studies have suggested that IL-6 plays a role in the 
regulation of glucose homeostasis and the enhancement
of lipid metabolism (Pedersen 2011; Al-Khalili et al.
2006; Carey et al. 2006; Klover et al. 2005; Petersen 
et al. 2005), and many studies have shown that skeletal
muscle is an important source of IL-6. Coll et al. found
that fatty acids, especially palmitate, can induce muscle
myocyte IL-6 expression and release in vitro (Coll et al.
2008; Jove et al. 2005; Weigert et al. 2004), and Pedersen
and colleagues demonstrated that IL-6 expression rap-
idly increases when resting human skeletal muscle is
subjected to exercise (Pedersen et al. 2001; Steensberg
et al. 2000). Exercise-induced IL-6 expression and release
is influenced by muscle energy availability, and some
studies have demonstrated that glucose ingestion during
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exercise attenuates exercise-induced increases in IL-6
plasma levels (Li et al. 2004; Lancaster et al. 2003;
Nieman et al. 2003). Other studies have shown that
muscle-derived IL-6 release increases during contrac-
tions when muscle glycogen levels are low (Keller et al.
2001; Steensberg et al. 2001). Experiments from our
laboratory have indicated that low pre-exercise muscle
glycogen content accelerates IL-6 expression in muscles
and IL-6 protein increases in the plasma (Tang et al.
2007). While previous studies have highlighted the neg-
ative correlation between IL-6 expression and muscle
glycogen content during exercise in vivo, there are no
studies to date that have examined the effects of glu-
cose deprivation on muscle-derived IL-6 expression and
protein release in skeletal muscle cell cultures in vitro.
Recently, fragmentary data have suggested that both
reactive oxygen species (ROS) and p38 mitogen-activated
protein kinase (p38MAPK) may play a role in regulat-
ing IL-6 expression. Fischer et al. (2004) have shown
that supplementation with the ROS scavengers vita-
mins C and E inhibits the release of IL-6 from contract-
ing human skeletal muscle, while Sano et al. (2001)
reported that the p38MAPK pathway is also critically
involved in ROS-mediated induction of IL-6 release by
angiotensin II in cardiac fibroblasts.
The purpose of this study was to test our hypothe-
sis that glucose deprivation enhances IL-6 expression
and protein release in C2C12 myocytes, and that this
enhancement is regulated via ROS signaling and the
p38MAPK pathway.
Methods
Cell culture
Mouse C2C12 myoblasts (Cell Center, Chinese Academy
of Medical Sciences, China) were maintained in 12-well
plates on Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Grand Island, NY, USA) supplemented with
10% fetal bovine serum, 100 U  mL−1 penicillin, and
100 μg  mL−1 streptomycin. When cells reached con-
fluence, the medium was switched to a differentiation
medium containing DMEM and 2% horse serum, which
was changed daily. The differentiated C2C12 cells fused
into myotubes 8 days after confluence.
Glucose deprivation induces IL-6 expression and
release
Differentiated C2C12 myotubes were placed in DMEM
medium containing 4.5 g  L−1 glucose (glucose control,
GC) or DMEM medium containing no glucose (glucose
deprivation, GD). Samples were incubated for 0, 6, 12, 18
and 24 hours, to measure IL-6 expression and protein
release over time. Following incubation, IL-6 mRNA levels
were analyzed using reverse-transcription–polymerase
chain reaction (RT–PCR), and IL-6 protein levels in the
medium were measured using ELISA.
Inhibition of ROS and the p38MAPK pathway
C2C12 myotubes were incubated with 10 mM N-acetyl-
L-cysteine (NAC; Sigma-Aldrich, St. Louis, MO, USA), the
precursor of the ROS scavenger glutathione, or 10 μM
SB203580 (Merck, Darmstadt, Germany), a p38MAPK
inhibitor, or alone (control) for 30 minutes. The myotubes
were then incubated in DMEM medium containing
4.5g L−1 glucose (glucose control, GC) or DMEM medium
containing no glucose (glucose deprivation, GD). There
were six treatment groups in this experiment: GC; 
GD; GC+NAC; GD+NAC; GC+SB203580; and GD+
SB203580. Following incubation, IL-6 protein levels in
the medium were measured using ELISA.
RT–PCR
IL-6 expression in C2C12 myotubes was analyzed using
RT–PCR. Total RNA was extracted using Trizol Reagent
(Invitrogen, Carlsbad CA, USA) according to the manu-
facturer’s instructions. RNA concentrations were esti-
mated by measuring absorbance at 260 nm, and
purity was assessed by 260 nm/280 nm absorbance
ratios (GeneQuant, Amersham Biosciences, Sweden).
Denaturation of 1.5 μg total RNA and 2 μM oligo dT
was carried out at 70°C for 5 minutes, immediately
cooled, and then reverse transcribed using 4U M-MLV
(Takara Bio, Otsu, Japan), 2U RNase Inhibitor, 0.4 mM
dNTPs, and RT Buffer in a total volume of 25 μL. The
reaction was reverse-transcribed at 42°C for 60 minutes
and at 70°C for 15 minutes. RT–PCR was performed in
a fluorescence temperature cycler (Rotor-Gene 6000,
Corbett, Australia), containing 10 μL SYBR PCR Master
Mix (Qiagen, Hilden, Germany), 0.5 μM Forward Primer,
0.5 μM Reverse Primer, and 5 ng cDNA in a total volume
of 20 μL. Amplification involved a three-step cycle re-
peated 45 times after pre-incubation at 95°C for 10 min-
utes: denaturation at 94°C for 20 seconds; annealing
at 58°C for 20 seconds; and extension at 72°C for 20
seconds. Primer pairs for the RT–PCR were, for the IL-6
gene (70 bp): 5–CTGCAAGAGACTTCCATCCAGTT–3 (for-
ward), 5–GAAGTAGGGAAGGCCGTGG–3 (reverse); and
for the β-actin gene (288 bp): 5–GCTACAGCTTCACCACC-
ACAG–3 (forward), 5–GGTCTTTACGGATGTCAACGTC–3
(reverse). IL-6 mRNA abundance was normalized to that
of β-actin.
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ELISA
The concentration of IL-6 protein in culture supernatants
was measured using commercially available ELISA kits
(eBioscience, San Diego, CA, USA). ELISA was performed
according to the manufacturer’s instructions. All sam-
ples were assayed in duplicate.
Statistical analyses
Results were expressed as mean ± standard deviation.
Data were analyzed using two-way ANOVA. Bonferroni
post hoc tests were used to compare differences between
means when significant main effects were detected.
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was
used for all analyses, and the significance level was set
at p < 0.05.
Results
Glucose deprivation induces IL-6 expression and
release
GD enhanced IL-6 expression in C2C12 myocytes com-
pared with GC. IL-6 expression increased significantly
at 18 hours (p < 0.01) and 24 hours (p < 0.05) under GD
conditions relative to GC (Figure 1A). IL-6 protein levels
in the medium in both GC and GD treatments increased
gradually from 0 to 24 hours. The GD treatment en-
hanced protein release significantly compared with
the GC treatment, but IL-6 protein levels also increased
under GD treatment at all of the time points (p < 0.05;
Figure 1B).
Glucose deprivation-induced IL-6 release is
mediated via ROS signaling and the 
p38MAPK pathway
As shown in Figure 2A, IL-6 protein level in the GC+NAC
treatment was significantly lower (p < 0.01) than in the
GC treatment. IL-6 protein level was also significantly
lower (p < 0.01) in the GD + NAC treatment compared
with the GD treatment. Tests of between-subjects effects
showed that glucose deprivation and NAC interacted
significantly (F = 30.125, p = 0.001), indicating that
NAC almost completely inhibited IL-6 protein release
under control conditions (normal culture), and glucose-
deprivation induced IL-6 protein release. As shown in
Figure 2B, IL-6 protein level in the GC + SB203580 treat-
ment was significantly lower (p < 0.01) than in the GC
treatment. IL-6 protein level was also significantly lower
(p < 0.01) in the GD + SB203580 treatment compared
with the GD treatment. Tests of between-subjects effects
showed that glucose deprivation and SB203580 inter-
acted significantly (F = 6.695, p = 0.034), indicating that
SB203580 inhibited IL-6 protein release under control
conditions (normal culture), and glucose deprivation-
induced IL-6 protein release to a lesser extent.
Discussion
Skeletal muscle is the largest organ in the human body
and produces cytokines (also called “myokines”), includ-
ing IL-6, which assert influences over other tissues as
well as skeletal muscle (Pedersen & Febbraio 2008).
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Fig. 1 Glucose deprivation induces IL-6 expression and release in C2C12 myocytes. Differentiated C2C12 myotubes were
placed in DMEM medium containing 4.5 g  L−1 glucose (glucose control, GC) or DMEM medium without glucose (glucose 
deprivation, GD) for 0, 6, 12, 18 or 24 hours. (A) IL-6 mRNA levels were analyzed using RT–PCR. (B) IL-6 protein levels in
media were analyzed using ELISA. Data are expressed as mean ± standard deviation. *p < 0.01 and †p < 0.05 (GD vs. GC at
respective time points).
Previously, muscle-derived exercise-induced IL-6 release
was considered a consequence of inflammation and
eccentric exercise-induced muscle damage, but recent
studies have shown that it is linked to metabolism, and
that energy availability influences its expression dur-
ing prolonged exercise (Fischer 2006; Steensberg et al.
2003; Gleeson 2000). In one of our previous studies,
rats exercising on a treadmill with low pre-exercise
muscle glycogen levels showed significantly higher lev-
els of plasma IL-6 during exercise (p < 0.01) (Tang et al.
2007). This study showed that IL-6 plasma concentration
is negatively correlated with muscle glycogen content
during exercise in vivo. Here, to eliminate the in vivo
effects of exercise and hormones, we used the C2C12
in vitro cell model to investigate the direct effects of
glucose deprivation on skeletal muscle-derived IL-6
expression and release. Our findings indicate that glu-
cose deprivation strongly enhances muscle-derived IL-6
expression and release in vitro. Combining our find-
ings with those of other studies, we hypothesize that
changes in the level of muscle-derived IL-6 signal that
muscle energy stores are reaching critically low levels.
The precise signaling events that mediate glucose
deprivation-induced IL-6, however, are not well under-
stood. Kosmidou et al. (2002) stated that ROS could
stimulate IL-6 production in skeletal muscle myotubes,
while Fischer et al. (2004) found that supplementation
with vitamins C and E (ROS scavengers) inhibits the
release of IL-6 from contracting human skeletal muscle.
These studies suggest that ROS, which are primarily
derived from mitochondria and crucial for redox 
signaling and other cellular events (Rhee 1999), are able
to stimulate IL-6 production in skeletal cells. We predict
that glucose deprivation results in a change in energy
metabolism within mitochondria, affecting ROS pro-
duction, and therefore IL-6 expression. Consistent with
Kosmidou et al.’s findings, our results show that the ROS
scavenger NAC almost completely inhibits both IL-6 pro-
tein release in normal cultures and glucose deprivation-
induced IL-6 protein release. The p38MAPK pathway is
also an important signaling pathway for regulating IL-6
expression. Chae et al. (2001) showed that blockading
the p38MAPK pathway inhibits inducible nitric oxide
synthase and IL-6 expression in MC3T3E-1 osteoblasts.
Studies have shown that the p38MAPK pathway may
be involved in ROS-mediated IL-6 production (Sano 
et al. 2001). Chan et al. (2004) reported that reduced
carbohydrate intake resulting in low muscle glycogen
leads to phosphorylation of p38MAPK in the nucleus,
which appears to be an upstream target for IL-6. Here,
we found that the p38MAPK inhibitor SB203580 inhib-
ited IL-6 protein release under normal culture condi-
tions, and also inhibited IL-6 protein release to a lesser
extent under glucose deprivation conditions. Our findings
clearly indicate that the p38MAPK pathway is involved
in glucose deprivation-induced IL-6 protein release in
C2C12 myocytes.
Taking a broader view of our result in the context of
other reports, we think glucose deprivation could alter
the energy metabolism of mitochondria as a result of
low muscle glucose, which may then directly or indi-
rectly affect muscle-derived IL-6 expression via ROS
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Fig. 2 Glucose deprivation-induced IL-6 release in C2C12 myocytes is mediated via ROS signaling and the P38MAPK pathway.
C2C12 myotubes were incubated with either 10 mM NAC (ROS scavenger) or 10 μM SB203580 (p38MAPK inhibitor) or alone
(negative control) for 30 minutes. The myotubes were then placed in DMEM media containing 4.5 g  L−1 glucose (glucose control,
GC) or DMEM media without glucose (glucose deprivation, GD) for 24 hours. IL-6 protein levels in the media were analyzed
using ELISA. Data are expressed as mean ± standard deviation. *p < 0.01 vs. GC; †p < 0.01 vs. GD.
signaling and the p38MAPK pathway. As a result, muscle-
derived IL-6 is released into the circulatory system,
where it may play a signaling role between contracting
muscle and other tissues. The role IL-6 plays in obesity
and insulin resistance remains controversial even after
many years of research (Allen & Febbraio 2010). To fur-
ther clarify the relationship between exercise-induced
skeletal muscle-derived IL-6 and insulin resistance and
obesity, we plan to conduct in vitro studies using elec-
trical stimulation to mimic muscle contraction, in order
to directly confirm our hypothesis that exercise-induced
skeletal muscle-derived IL-6 can enhance energy metab-
olism and reduce insulin resistance.
Our study has shown that glucose deprivation induces
IL-6 expression and release in C2C12 myocytes and
that this glucose deprivation-induced IL-6 release is
mainly mediated via ROS signaling. Skeletal muscle-
derived IL-6 may play an important role in energy metab-
olism during exercise.
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